Pharma & biotech

ALK sees no approval obstacles for children's tablet following "surprisingly good" data

The allergy company’s house dust mite tablet could be on the pediatric market in 2024/2025.
ALK's new head of R&D, Henriette Mersebach, is convinced new data will be enough to convince drug regulators to expand the indication of a house dust mite tablet treatment to include children | Photo: Magnus Møller
ALK's new head of R&D, Henriette Mersebach, is convinced new data will be enough to convince drug regulators to expand the indication of a house dust mite tablet treatment to include children | Photo: Magnus Møller
By Albert Rønning-Andersson, translated by Daniel Pedersen

The way seems all but cleared for Danish allergy company ALK submitting its house dust mite tablet on a market targeting more than just adults and adolescents, but children with allergic rhinitis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs